UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
Go back to UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science| (NYSE: UCB) | Delayed: 34.63 +0.36 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.27 | 52 Week High | $ | |||
| Open | $34.50 | 52 Week Low | $ | |||
| Day High | $34.77 | P/E | N/A | |||
| Day Low | $34.47 | EPS | $ | |||
| Volume | 966,414 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 158.72 +0.71 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.01 | 52 Week High | $46.25 | |||
| Open | $157.44 | 52 Week Low | $32.74 | |||
| Day High | $160.08 | P/E | N/A | |||
| Day Low | $157.07 | EPS | $0.00 | |||
| Volume | 12,696 | |||||
